Merck Won't Join Inversion Craze, CEO Says
Pharmaceutical companies are heavily represented in this year's roster of inversion deals, but Merck & Co. Inc. won't be joining the pack according to CEO Kenneth Frazier, who in an earnings...To view the full article, register now.
Already a subscriber? Click here to view full article